Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from BTIG Research

Key Points

• BTIG Research has reiterated a "buy" rating for Monopar Therapeutics (NASDAQ:MNPR) with a price target of $87.00, indicating a potential upside of 76.21% from its previous close.
• Monopar's stock has shown significant volatility, with a 12-month high of $54.30 and a low of $3.65, alongside a current market cap of approximately $304.64 million.
• Insider transactions indicate active trading, with both the CEO and a director selling shares at $40.00 each, resulting in a notable decrease in their ownership stakes.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "buy" rating restated by BTIG Research in a research note issued to investors on Monday,Benzinga reports. They presently have a $87.00 price target on the stock. BTIG Research's price objective points to a potential upside of 76.21% from the company's previous close.

MNPR has been the subject of several other reports. Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright assumed coverage on Monopar Therapeutics in a research note on Tuesday, August 26th. They issued a "buy" rating and a $70.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $74.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. Chardan Capital restated a "buy" rating and set a $60.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, August 13th. Finally, Oppenheimer began coverage on shares of Monopar Therapeutics in a research report on Wednesday, September 3rd. They issued an "outperform" rating and a $77.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, Monopar Therapeutics presently has an average rating of "Buy" and a consensus price target of $71.75.

Monopar Therapeutics Price Performance

Shares of MNPR stock traded up $0.15 during trading hours on Monday, reaching $49.37. The company had a trading volume of 14,458 shares, compared to its average volume of 39,477. The business has a fifty day simple moving average of $39.33 and a 200-day simple moving average of $36.98. Monopar Therapeutics has a 12 month low of $3.65 and a 12 month high of $54.30. The company has a market cap of $304.64 million, a price-to-earnings ratio of -14.57 and a beta of 1.20.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.12. On average, equities research analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Activity at Monopar Therapeutics

In related news, Director Christopher M. Starr sold 16,800 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the transaction, the director owned 5,173 shares in the company, valued at $206,920. The trade was a 76.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer directly owned 73,472 shares of the company's stock, valued at approximately $2,938,880. The trade was a 18.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,504 shares of company stock worth $1,700,160 in the last 90 days. Company insiders own 20.50% of the company's stock.

Institutional Investors Weigh In On Monopar Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of MNPR. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Monopar Therapeutics in the 2nd quarter worth approximately $34,000. AlphaQuest LLC bought a new stake in Monopar Therapeutics in the first quarter worth $44,000. JPMorgan Chase & Co. grew its stake in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after acquiring an additional 1,821 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Monopar Therapeutics during the second quarter valued at $80,000. Finally, New York State Common Retirement Fund bought a new position in shares of Monopar Therapeutics during the second quarter valued at $104,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.